@EHahnMD missed the citation, was this it? https://t.co/Xibze6PWM5
Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US https://t.co/HnNCjeDX43 #CBD #CBDlife #cbdoil
In 26 children with Refractory Epilepsy over a 4-year period, cannabidiol was effective in 26.9%. It was well tolerated in only 20% of patients, but 80.8% had adverse events (23.1% serious AEs). Decreased appetite and weight, and diarrhea were frequent htt
RT @JamesBurton65: Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expand…
RT @aushempparty: Columbia University, New York, US - Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refracto…
RT @aushempparty: Columbia University, New York, US - Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refracto…
Columbia University, New York, US - Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US. Abstract BACKGROUND: Purified cannabidiol is a... https://t.co/2gcQM9GI
RT @JamesBurton65: Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expand…
Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US. - PubMed - NCBI https://t.co/nMBjltvkVB
This study is observational, not trying to discover causes, bad or good, but it is important to see that we still have much to learn, & very real potential concern that #cannabinoids may present to developing minds/systems. https://t.co/kimUoJuln3
STUDY. Worrying data shows #CBD may not be as effective and well tolerated by children with #epilepsy as previously thought. Over four years, only effective in 26.9% of patients and 23.1% had serious side effects #cannabis #EndOurPain https://t.co/j0txBCnc
STUDY. Worrying data shows #CBD may not be as effective and well tolerated by children with #epilepsy as previously thought. Over four years, only effective in 26.9% of patients and 23.1% had serious side effects #cannabis #EndOurPain https://t.co/j0txBCnc
STUDY. Worrying data shows #CBD may not be as effective and well tolerated by children with #epilepsy as previously thought. Over four years, only effective in 26.9% of patients and 23.1% had serious side effects #cannabis #EndOurPain https://t.co/j0txBCnc
STUDY. Worrying data shows #CBD may not be as effective and well tolerated by children with #epilepsy as previously thought. Over four years, only effective in 26.9% of patients and 23.1% had serious side effects #cannabis #EndOurPain https://t.co/j0txBCnc
RT @neuralnetwork19: 1/ An important reminder that we still have a long way to go in proving the safety and efficacy of CBD. A recent repor…
STUDY. Worrying data shows #CBD may not be as effective and well tolerated by children with #epilepsy as previously thought. Over four years, only effective in 26.9% of patients and 23.1% had serious side effects #cannabis #EndOurPain https://t.co/j0txBCnc
STUDY. Worrying data shows #CBD may not be as effective and well tolerated by children with #epilepsy as previously thought. Over four years, only effective in 26.9% of patients and 23.1% had serious side effects #cannabis #EndOurPain https://t.co/j0txBCnc
STUDY. Worrying data shows #CBD may not be as effective and well tolerated by children with #epilepsy as previously thought. Over four years, only effective in 26.9% of patients and 23.1% had serious side effects #cannabis #EndOurPain https://t.co/j0txBCnc
Concerning effects with high doses, but only small numbers in study
STUDY. Worrying data shows #CBD may not be as effective and well tolerated by children with #epilepsy as previously thought. Over four years, only effective in 26.9% of patients and 23.1% had serious side effects #cannabis #EndOurPain https://t.co/j0txBCnc
RT @TweeterReynolds: STUDY. Worrying data shows #CBD may not be as effective and well tolerated by children with #epilepsy as previously th…
STUDY. Worrying data shows #CBD may not be as effective and well tolerated by children with #epilepsy as previously thought. Over four years, only effective in 26.9% of patients and 23.1% had serious side effects #cannabsi #EndOurPain https://t.co/79MvzZMz
STUDY. Worrying data shows #CBD may not be as effective and well tolerated by children with #epilepsy as previously thought. Over four years, only effective in 26.9% of patients and 23.1% had serious side effects #cannabsi #EndOurPain https://t.co/j0txBCnc
What has never been further studied: CBD caused transient "glaucoma" in human and animal studies. Are we trading reduced seizures for blindness?
CBD is not a miracle drug!
Small sample size. CBD may not work for all kids. Study from #Toronto #SickKids hospital had better success with different mix of CBD with THC. We certainly need more #research Not following standard #clinicaltrials process.
RT @PoppotGroup: Serious adverse events, reported in 6 patients (23.1%), included status epilepticus in 3, catatonia in 2, hypoalbuminemia…
RT @PoppotGroup: Serious adverse events, reported in 6 patients (23.1%), included status epilepticus in 3, catatonia in 2, hypoalbuminemia…
RT @PoppotGroup: Serious adverse events, reported in 6 patients (23.1%), included status epilepticus in 3, catatonia in 2, hypoalbuminemia…
Serious adverse events, reported in 6 patients (23.1%), included status epilepticus in 3, catatonia in 2, hypoalbuminemia in 1. Fifteen patients (57.7%) discontinued cannabidiol for lack of efficacy, 1 because status epilepticus,1 for severe weight loss. h
RT @yuji_masataka: 難治生てんかんに対するCBDの長期投与の試験。 およそ1/4はその他に手段のなかった症状が改善し継続。 二年間の使用で明らかな耐性はなし。 https://t.co/klDMXlGfwI
RT @neuralnetwork19: 1/ An important reminder that we still have a long way to go in proving the safety and efficacy of CBD. A recent repor…
まーじーでー これが本当だとしても、日本ではまず実施されないだろうな。
RT @effatma: Over half of pediatric epilepsy patients discontinued CBD for lack of efficacy. https://t.co/4PFP7OK6mA
RT @romix10tm: 日本の医師も医療大麻を推奨されています。 https://t.co/N8nwhFKdTW
RT @yuji_masataka: 難治生てんかんに対するCBDの長期投与の試験。 およそ1/4はその他に手段のなかった症状が改善し継続。 二年間の使用で明らかな耐性はなし。 https://t.co/klDMXlGfwI
RT @AmirEnglund: Side effects of CBD in children with treatment resistant epilepsy who've been treated for up to 4yrs - https://t.co/qam9…
RT @colly_santa420: 数年前てんかん持ちの友達が重機を運転中気を失い通学途中の小学生の列に突っ込み、死人が出る大事故を起こしてしまった。しかし大麻でてんかんが治るなら大麻を取り締まるクソバビロンたちに、言ってやりたい。てんかん持ちの友達と子供をひき殺された親は…
RT @ikuemiroku: 素晴らしい! https://t.co/OHOhb2hVKL
RT @neuralnetwork19: 1/ An important reminder that we still have a long way to go in proving the safety and efficacy of CBD. A recent repor…
日本の医師も医療大麻を推奨されています。
RT @profhrs: “Most patients discontinued cannabidiol because of inefficacy, the majority doing so by 6 months. The retention rate at 2 year…
RT @yuji_masataka: 難治生てんかんに対するCBDの長期投与の試験。 およそ1/4はその他に手段のなかった症状が改善し継続。 二年間の使用で明らかな耐性はなし。 https://t.co/klDMXlGfwI
RT @yuji_masataka: 難治生てんかんに対するCBDの長期投与の試験。 およそ1/4はその他に手段のなかった症状が改善し継続。 二年間の使用で明らかな耐性はなし。 https://t.co/klDMXlGfwI
RT @ikuemiroku: 素晴らしい! https://t.co/OHOhb2hVKL
RT @yuji_masataka: 難治生てんかんに対するCBDの長期投与の試験。 およそ1/4はその他に手段のなかった症状が改善し継続。 二年間の使用で明らかな耐性はなし。 https://t.co/klDMXlGfwI
RT @yuji_masataka: 難治生てんかんに対するCBDの長期投与の試験。 およそ1/4はその他に手段のなかった症状が改善し継続。 二年間の使用で明らかな耐性はなし。 https://t.co/klDMXlGfwI
RT @ikuemiroku: 素晴らしい! https://t.co/OHOhb2hVKL
RT @ikuemiroku: 素晴らしい! https://t.co/OHOhb2hVKL
RT @yuji_masataka: 難治生てんかんに対するCBDの長期投与の試験。 およそ1/4はその他に手段のなかった症状が改善し継続。 二年間の使用で明らかな耐性はなし。 https://t.co/klDMXlGfwI
RT @ikuemiroku: 素晴らしい! https://t.co/OHOhb2hVKL
素晴らしい!
RT @yuji_masataka: 難治生てんかんに対するCBDの長期投与の試験。 およそ1/4はその他に手段のなかった症状が改善し継続。 二年間の使用で明らかな耐性はなし。 https://t.co/klDMXlGfwI
RT @yuji_masataka: 難治生てんかんに対するCBDの長期投与の試験。 およそ1/4はその他に手段のなかった症状が改善し継続。 二年間の使用で明らかな耐性はなし。 https://t.co/klDMXlGfwI
難治生てんかんに対するCBDの長期投与の試験。 およそ1/4はその他に手段のなかった症状が改善し継続。 二年間の使用で明らかな耐性はなし。 https://t.co/klDMXlGfwI
RT @neuralnetwork19: 1/ An important reminder that we still have a long way to go in proving the safety and efficacy of CBD. A recent repor…
RT @neuralnetwork19: 1/ An important reminder that we still have a long way to go in proving the safety and efficacy of CBD. A recent repor…
RT @AmirEnglund: Side effects of CBD in children with treatment resistant epilepsy who've been treated for up to 4yrs - https://t.co/qam9…
RT @neuralnetwork19: 1/ An important reminder that we still have a long way to go in proving the safety and efficacy of CBD. A recent repor…
RT @effatma: Over half of pediatric epilepsy patients discontinued CBD for lack of efficacy. https://t.co/4PFP7OK6mA
RT @effatma: Over half of pediatric epilepsy patients discontinued CBD for lack of efficacy. https://t.co/4PFP7OK6mA
RT @profhrs: “Most patients discontinued cannabidiol because of inefficacy, the majority doing so by 6 months. The retention rate at 2 year…
RT @neuralnetwork19: 1/ An important reminder that we still have a long way to go in proving the safety and efficacy of CBD. A recent repor…
RT @effatma: Over half of pediatric epilepsy patients discontinued CBD for lack of efficacy. https://t.co/4PFP7OK6mA
RT @effatma: Over half of pediatric epilepsy patients discontinued CBD for lack of efficacy. https://t.co/4PFP7OK6mA
RT @profhrs: “Most patients discontinued cannabidiol because of inefficacy, the majority doing so by 6 months. The retention rate at 2 year…
Over half of pediatric epilepsy patients discontinued CBD for lack of efficacy.
RT @neuralnetwork19: 1/ An important reminder that we still have a long way to go in proving the safety and efficacy of CBD. A recent repor…
1/ An important reminder that we still have a long way to go in proving the safety and efficacy of CBD. A recent report shows 80% of pediatric epilepsy reporting serious side effects from long-term CBD use. https://t.co/w6S0TE1SzW
RT @AmirEnglund: Side effects of CBD in children with treatment resistant epilepsy who've been treated for up to 4yrs - https://t.co/qam9…
Long-Term Safety, Tolerability, and Efficacy of #Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US. - @PubMed - @NCBI https://t.co/QkskGvsEFd
RT @AmirEnglund: Side effects of CBD in children with treatment resistant epilepsy who've been treated for up to 4yrs - https://t.co/qam9…
RT @AmirEnglund: Side effects of CBD in children with treatment resistant epilepsy who've been treated for up to 4yrs - https://t.co/qam9…
RT @profhrs: “Most patients discontinued cannabidiol because of inefficacy, the majority doing so by 6 months. The retention rate at 2 year…
RT @AmirEnglund: Side effects of CBD in children with treatment resistant epilepsy who've been treated for up to 4yrs - https://t.co/qam9…
RT @AmirEnglund: Side effects of CBD in children with treatment resistant epilepsy who've been treated for up to 4yrs - https://t.co/qam9…
RT @AmirEnglund: Side effects of CBD in children with treatment resistant epilepsy who've been treated for up to 4yrs - https://t.co/qam9…
RT @AmirEnglund: Side effects of CBD in children with treatment resistant epilepsy who've been treated for up to 4yrs - https://t.co/qam9…
RT @profhrs: “Most patients discontinued cannabidiol because of inefficacy, the majority doing so by 6 months. The retention rate at 2 year…
“Most patients discontinued cannabidiol because of inefficacy, the majority doing so by 6 months. The retention rate at 2 years was 34.6% (9/26)”
Side effects of CBD in children with treatment resistant epilepsy who've been treated for up to 4yrs - https://t.co/qam9RKra6c
RT @CNSdrughunter: Great catch @LalDennis! 4-year long-term data on Epidiolex. Much information on side effects, adverse effects and also l…
Pequeño estudio sobre cannabidiol y epilepsias refractarias
Great catch @LalDennis! 4-year long-term data on Epidiolex. Much information on side effects, adverse effects and also long-term efficacy.
Small but interesting study: Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US. https://t.co/mrTQe7nckh https://t.co/h5iNLdkeQD
Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US. https://t.co/w92A0I8oHz